Skip to main content

Clinical trial IMpassion 030 (BIG 16-05/AFT-27/WO39391)

A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer

Organ Breast
Trial status Trial closed
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Roche
EudraCT Identifier 2016-003695-47
Inclusion criteria Non-metastatic operable. TNBC. Adjuvant. Atezolizumab
Last update